All In Biotech

Drug Trial Radar · NCT05160922

Crizotinib Continuation Clinical Study

CRIZOTINIB MASTER PROTOCOL: AN OPEN-LABEL CONTINUATION STUDY FOR PARTICIPANTS CONTINUING FROM PFIZER-SPONSORED CRIZOTINIB CLINICAL STUDIES

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

27

Actual

Start

Dec 27, 2021

Primary completion

Mar 21, 2028

Study completion Mar 21, 2028

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Dec 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this continuation study is to provide continued access to crizotinib treatment for eligible participants from a current Pfizer sponsored crizotinib clinical study that is planned to close.

Conditions

  • NSCLC
  • ALCL
  • IMT

Interventions

  • crizotinibDrug

    crizotinib oral treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events leading to permanent discontinuation of study interventionTime frame: Baseline up to approximately 5 years
  2. Number of serious adverse events reported for all participantsTime frame: Baseline up to approximately 5 years

Locations

13 sites in 5 countries. Site status is shown where the registry gives one.

  • Shanghai Chest Hospital

    Shanghai, China

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China

  • Fujian Province Oncology Hospital

    Fuzhou, Fujian, China

  • Sun Yat-Sen University Cancer center

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Guangzhou Medical University.

    Guangzhou, Guangzhou, China

  • Jilin Cancer Hospital

    Changchun, Jilin, China

  • West China Hospital of Sichuan University

    Wuhou District, Sichuan, China

  • The First Affiliated Hospital of College of Medicine,Zhejiang University

    Hangzhou, Zhejiang, China

  • ASST Monza

    Monza, MB, Italy

  • National Hospital Organization Nagoya Medical Center

    Nagoya, Aichi-ken, Japan

  • Limited Liability Company "EuroCityClinic"

    Saint Petersburg, Russia

  • National Taiwan University Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.